Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 11, 2004

Primary Completion Date

September 15, 2024

Study Completion Date

October 15, 2024

Conditions
brca1 Mutation Carrierbrca2 Mutation CarrierBreast Cancer
Interventions
BIOLOGICAL

therapeutic estradiol

0.35mg/100ul per day as a nasal spray

DRUG

deslorelin

1mg/100ul per day as a nasal spray

DRUG

therapeutic testosterone

0.275mg/100ul per day as a nasal spray

PROCEDURE

therapeutic conventional surgery

Undergo risk reduction mastectomy

OTHER

active surveillance

Undergo continued surveillance

PROCEDURE

quality-of-life assessment

Ancillary studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91010-3000

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER